FDA approves Novartis’ Afinitor
November 1, 2010Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis
Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …
TranslateMedia ranked 4th in UK Deloitte Technology Fast 50 for 2010
November 1, 2010Business Services
TranslateMedia announced today that it has been ranked 4th in this year’s UK Deloitte Technology Fast 50. The Technology Fast …
Pfizer to seek US approval for crizotinib next year
November 1, 2010Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer
Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
German rebates to cost pharma 1 billion euro
November 1, 2010Sales and Marketing BPI, German pharma market, Germany, Gesetzliche Krankenversicherung, healthcare costs
The pharma industry will contribute over 1 billion euro ($1.4 billion) to Germany’s cost-containment efforts by the end of 2010. …
GSK signs rare diseases deal with Amicus
November 1, 2010Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones
GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …
Cross-functional marketing leadership
November 1, 2010Sales and Marketing Nikki Atkins, WG Consulting Healthcare, leadership, marketing strategies, pharma marketing
Building a multi-disciplinary team across a pharma company is a tough challenge – but the demands of the modern development …
Patent expiries bite into AstraZeneca revenues
October 29, 2010Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel
Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …
MabThera gains maintenance therapy licence
October 29, 2010Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma
Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …
Watson submits Crestor copycat
October 28, 2010Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent
Watson Pharmaceuticals is seeking to launch a generic version of AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …
Rep’s shotgun request misfires
October 28, 2010Sales and Marketing ABPI Code of Practice, PMCPCA, Sanofi-Aventis
Sanofi-Aventis has been found in breach of the ABPI Code over the conduct of one of its representatives in relation …
GSK makes record whistleblower payout
October 28, 2010Manufacturing and Production Cheryl Eckard, FDA, GSK, GlaxoSmithKline, manufacturing compliance, whistle blower
GlaxoSmithKline has officially agreed to plead guilty to distributing adulterated drugs made at its now-closed facility in Cidra, Puerto Rico, …
Engaging the digital audience
October 28, 2010Medical Communications Andy Bell, Huntsworth Health, Jon Clark, Talking Point, digital marketing, digital pharma
We live in exciting times. With the rise of social media, people are changing the way they consume information. As …
NICE refuses cancer drugs Arzerra, Torisel and Levact
October 27, 2010Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs
NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …
Intercell appoints Staph Leavenworth Bakali
October 27, 2010Research and Development Intercell, Staph Leavenworth Bakali, appointment, research and development
Austrian biotech company Intercell has appointed Staph Leavenworth Bakali as chief business officer. He will have key responsibilities for the …
£600m confirmed for three year Cancer Drugs Fund
October 27, 2010Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing
The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …
Contract research news in brief
October 27, 2010Research and Development Almac, Kinaxo, MediData Solutions, Quintiles, Ricerca Biosciences, Southern Research Institute, Venn Life Sciences, biofocus, contract research
Our latest crop of contract research news includes updates from Quintiles, Venn Life Sciences, Medidata Solutions, Southern Research Institute, Ricerca …
Health outcomes – does anything else matter?
October 27, 2010Research and Development Les Rose, evidence-based medicine, healthcare outcomes, randomised controlled trials
So the mould of British politics has been broken, and we now have a government with probably a broader range …
Pharma engages HTA bodies in early-stage drug discussions
October 27, 2010Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta
Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …
Digital Pharma: UK’s online dementia mentors
October 26, 2010Medical Communications Alzheimer's disease, Comprehensive Spending Review, Digital Pharma blog, dementia, patient education
The Department of Health is looking for hundreds of people to become online dementia mentors as part of it ongoing …
Sanofi moves teriflunomide into phase III MS trials
October 26, 2010Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide
Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
